- Home
- JFIN vs AVXL Comparison
JFIN vs AVXL Comparison
Compare JFIN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFIN
- AVXL
- Stock Information
- Founded
- JFIN 2011
- AVXL 2004
- Country
- JFIN China
- AVXL United States
- Employees
- JFIN N/A
- AVXL N/A
- Industry
- JFIN Finance: Consumer Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JFIN Finance
- AVXL Health Care
- Exchange
- JFIN Nasdaq
- AVXL Nasdaq
- Market Cap
- JFIN N/A
- AVXL 779.5M
- IPO Year
- JFIN 2019
- AVXL N/A
- Fundamental
- Price
- JFIN $14.04
- AVXL $8.52
- Analyst Decision
- JFIN
- AVXL Strong Buy
- Analyst Count
- JFIN 0
- AVXL 2
- Target Price
- JFIN N/A
- AVXL $44.00
- AVG Volume (30 Days)
- JFIN 249.1K
- AVXL 1.0M
- Earning Date
- JFIN 03-27-2025
- AVXL 05-08-2025
- Dividend Yield
- JFIN 6.37%
- AVXL N/A
- EPS Growth
- JFIN N/A
- AVXL N/A
- EPS
- JFIN 2.73
- AVXL N/A
- Revenue
- JFIN $794,759,901.00
- AVXL N/A
- Revenue This Year
- JFIN N/A
- AVXL N/A
- Revenue Next Year
- JFIN N/A
- AVXL N/A
- P/E Ratio
- JFIN $5.12
- AVXL N/A
- Revenue Growth
- JFIN 6.11
- AVXL N/A
- 52 Week Low
- JFIN $4.00
- AVXL $3.25
- 52 Week High
- JFIN $16.22
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- JFIN 63.47
- AVXL 40.76
- Support Level
- JFIN $12.52
- AVXL $8.35
- Resistance Level
- JFIN $16.22
- AVXL $9.87
- Average True Range (ATR)
- JFIN 1.37
- AVXL 0.54
- MACD
- JFIN 0.18
- AVXL -0.09
- Stochastic Oscillator
- JFIN 65.99
- AVXL 9.19
Stock Price Comparison Chart: JFIN vs AVXL
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.